Study Inclusion Criteria
Studies were eligible if they: (1) enrolled ischemic stroke patients treated with intravenous rtPA, (either into observational cohorts or the treatment arms of trials of rtPA); (2) measured variables available to a clinician before the infusion of rtPA; (3) were primary studies rather than pooling projects (to prevent double counting of the individual cohorts); and (4) recorded at least 10 ICH within the first 10 days after treatment, because this is the minimum number needed to measure an association reliably. 8 
Search Strategy
We searched Medline and EMBASE from inception to August 2011 (Supplementary Materials I), and we supplemented this by searching our personal files and citations of relevant studies. We did not limit our search by language.
Data Extraction
Three authors (W.W., K.B.S., and P.F.) read the abstracts of retrieved studies and reviewed the full text of those that appeared relevant. Two authors read each abstract and resolved differences by discussion with a third author if necessary. We extracted data into an electronic database. We recorded study-level characteristics that might bias the estimates of associations within each study: the nature of the study (randomized controlled trial or observational cohort); losses to follow-up; and statistical methods. We then recorded (or calculated from figure presented) the odds ratios (OR) and 95% confidence intervals (CI) between baseline variables and ICH. For each OR, we recorded the degree of adjustment for confounding (for age, stroke severity, or other factors), the method of measurement of the baseline variables, the number of ICH, the number of patients with the baseline variables measured, and the definition of ICH used by the investigators. When a study gave both unadjusted and adjusted OR, we recorded the adjusted OR. Where a continuous variable was not examined continuously but was dichotomized or a dichotomy could be calculated, we recorded the cut-off point; when a variable had more divisions and a dichotomy could not be calculated, we recorded the comparison of the extreme thirds. When a study defined ICH in several ways we used the definition of symptomatic ICH, which gave the greatest number of ICH, unless it was clear that the focus of the study was to record a particular hemorrhage definition. Data were extracted twice for each study to reduce transcription errors. We tried to avoid double counting of cohorts, which would have artificially increased the precision of the effect sizes.
Definition of ICH
We defined clinically important post-rtPA ICH as "any visible hemorrhage associated with any neurological deterioration," 9 "any visible hemorrhage with significant neurological deterioration," 10, 11 "parenchymal hemorrhage with or without neurological deterioration," 12 and "parenchymal hemorrhage with significant neurological deterioration" 13 (Supplementary Materials II).
Analysis
We calculated a weighted estimate of the proportions of patients with each definition of ICH by meta-analyzing the inverse varianceweighted proportions from each study. For each association, we calculated the natural log of the OR and the standard error of the log ratio. We used random-effects meta-analysis, which assumes that the true underlying effect size varies between studies, to calculate summary OR and 95% CI. We used random-effects meta-regression to explore the extent to which study design, degree of adjustment for confounding factors, and definition of ICH explained between-study heterogeneity for those associations with >10 studies. We assessed heterogeneity between study estimates using the I 2 statistic, 14 with thresholds for low, moderate, and high degrees of heterogeneity and very high heterogeneity at 25%, 50%, and 75%, respectively. We inspected funnel plots and used Egger test to examine for evidence of publication bias 15 for those associations described in >10 studies. We used Stata 11 for the analysis.
Results

Included Studies
We identified 55 studies that met our inclusion criteria (Figure 1 ) that measured associations between baseline variables and post-rtPA ICH (median 2 associations per study; interquartile range, 1-6), a total of 3953 ICH in 65 264 acute ischemic stroke patients. Studies were based in Europe (24) , North America (14) , or East Asia (4), or they were multiregional (13) . Almost all studies used rtPA at the currently recommended dose of 0.9 mg/kg; 54 papers were written in English and 1 was written in Japanese. Eleven studies were of rtPA-treated patients from randomized controlled trials of rtPA and other acute stroke treatments, and 44 were prospective cohort studies. No study reported losses to follow-up before the occurrence of post-rtPA ICH. The analysis examined 43 baseline variables, each of which was examined in between 1 and 22 studies. For each variable there were a median of 136 hemorrhages (interquartile range, 33-347) and a median of 3215 stroke patients treated with rtPA (interquartile range, 640-10 707). The characteristics of the included studies are summarized in Supplementary Tables III and IV .
Definition of Post-rtPA ICH
Most studies used a definition of "any visible hemorrhage with any neurological deterioration" (26/55), fewer used the definition "any visible hemorrhage with significant neurological deterioration" (12/55) and "parenchymal hemorrhage with or without neurological deterioration" (9/55), and fewest used the definition "parenchymal hemorrhage with significant neurological deterioration" (8/55). There was variation in the timing of the measurement of hemorrhage for each hemorrhage definition. (Table) There was ≈3-fold difference in the proportion of patients with a reported post-rtPA ICH between studies that reported hemorrhage as "parenchymal hemorrhage with significant neurological deterioration" (4.1%) and those that reported hemorrhage as "parenchymal hemorrhage with or without neurological deterioration" (12.2% ; Table) . The definition "any hemorrhage with significant deterioration" was the only definition for which the proportion of patients with post-rtPA ICH varied little between studies (ie, low statistical heterogeneity; I 2 =0%). Figure 2 shows the results of a meta-analysis for each of the 43 Higher blood glucose levels were associated with a significantly higher risk of post-rtPA ICH, with a moderate degree of heterogeneity (I 2 =26%) when modeled as a continuous variable (OR, 1.10 per mmol/L), and when divided at 8 or 10 mmol/L (I 2 =39%). We found surprisingly few associations between systolic blood pressure with post-rtPA ICH (6 studies) with a high degree of heterogeneity in the size of the estimates from different studies, whether examined as a continuous variable (I 2 =67%) or dichotomous variable (I 2 =35%).
Associations Between Baseline Variables With Post-rtPA Hemorrhage
The overall estimate was consistent with a small decrease and a larger increase in the risk of ICH with higher blood pressure. Later timing of thrombolysis did not increase the risk of ICH significantly, although the studies reported time as a dichotomous rather than continuous variable.
The presence of a visible brain imaging lesion was associated with a higher risk of ICH, whether recorded as the "presence of any lesion" vs "no visible lesion" (OR, 2.39; I . A random-effects meta-regression analysis showed no significant effect of the definition of the lesion size on the strength of the association (>33% of middle cerebral artery territory vs any visible lesion: OR, 2.07; 95% CI, 0.81-5.27; P=0·12). The presence vs absence of leukoaraiosis on baseline imaging was associated with an increased risk of post-rtPA hemorrhage (OR, 2·45) with low heterogeneity.
Assessment of Heterogeneity
We were unable to demonstrate that the definition of ICH, study design (randomized trial vs observational cohort), or degree of adjustment for confounding factors in the original studies explained a statistically significant proportion of 
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between-study heterogeneity in the strength of the association between post-rtPA ICH with any of: age; smoking; any computed tomography low density; National Institutes of Health Stroke Scale score; gender; diabetes; previous hypertension; glucose; visible brain lesion; use of previous antiplatelets; and atrial fibrillation (baseline variables with >10 measured associations). Two studies 16, 17 compared the association between baseline variables with different ways of defining post-rtPA ICH within the study population; there was no evidence in these studies that hemorrhage definition explained heterogeneity in the strength of the associations between post-rtPA ICH with antiplatelet agents, National Institutes of Health Stroke Scale, age, systolic blood pressure, or glucose level.
Assessment of Publication Bias
We found no evidence for publication bias for any of the associations of post-rtPA ICH with age, smoking, any computed tomography low density, National Institutes of Health Stroke Scale score, gender, diabetes, previous hypertension, glucose, visible brain lesion, and atrial fibrillation. There was, however, evidence of significant small study bias for the association between post-rtPA ICH with the prescription of antiplatelets (P<0.001; Egger bias coefficient 1.92; 95% CI, 1.15-2.69), although 1 study had a significant influence on this statistic.
Discussion
We found moderate and positive associations between post-rtPA ICH with older age, higher neurological impairment, higher plasma glucose, antiplatelets, statins, computed tomography changes of acute ischemic stroke, leukoarioisis, and the presence of atrial fibrillation, diabetes, previous ischemic heart or cerebral vascular diseases, and congestive cardiac failure. The associations of these factors with post-rtPA hemorrhage were modest and they are unlikely-at least when measured individually-to predict whether an individual patient will experience a post-rtPA ICH. The presence or absence of any of these variables does not appear to be a reliable way to decide whether to treat an acute stroke patient with intravenous rtPA.
The definition of ICH used by each study had an effect on the prevalence of ICH but did not materially alter the relative measures of association of baseline variables with the occurrence of ICH.
The apparently protective effect of smoking on post-rtPA ICH is probably analogous to the "smoker's paradox" first observed in large trials of thrombolysis for myocardial infarction. There is a similar apparent improvement in survival of smokers after ischemic stroke. 18 The improved survival compared with that of nonsmokers after myocardial infarction is largely accounted for by the younger age and less advanced atherosclerosis at the time of presentation. Because we only had access to group data, we have not been able to examine whether this association in stroke patients attenuated after adjusting for age and degree of neurological impairment.
Antiplatelet agents were associated with an increased risk of post-rtPA ICH. We did not observe a significant doseresponse with the number of antiplatelet agents prescribed across studies. The recent ARTIS trial tested the addition of aspirin to rtPA, and demonstrated an increased risk of postrtPA ICH in patients treated with aspirin (risk ratio 2.78, 95% CI:1.01 to 7.63). This is similar to the association we observed in our systematic review (OR 2.08 95% CI: 1.46 to 2.97), and strongly suggests a causal relationship between antiplatelets and the risk of intracranial haemorrhage. 19 Most of the clinical risk factors for ICH after rtPA also have been associated with poor prognosis after stroke. 20 The extent to which confounding by other risk factors explains each association is difficult to judge from this systematic review, because even though we could not demonstrate a significant attenuation in the size of the associations with increasing adjustment for age, stroke severity, or other factors, these analyses lacked statistical power because the comparisons were made between studies rather than within study. Systematic reviews of prognostic variables are methodologically challenging, and methods for such reviews are developing and improving. We did not search the gray literature, and so we may have missed some studies, although we did not find much evidence of publication or other small study biases in the associations we measured (other than for antiplatelet medication). Despite our efforts to prevent it, it is possible that some cohorts were double-counted, which may have led to inappropriately overstated precision of the reported effect sizes.
We did not find a sufficient number of studies that examined either systolic blood pressure or timing of thrombolysis as continuous variables to draw strong conclusions. Where we were able to examine time to treatment, it was simply dichotomized into later vs earlier treatment, and the pooled estimate for association between later time of treatment and ICH was not statistically significant. This was consistent with the results of an analysis of pooled data from the ATLANTIS, ECASS, and NINDS trials, which did not show any clear gradient in the risk of ICH with increasing delay to treatment. 21 This may reflect confounding by the degree of neurological impairment (because patients with more severe strokes tend to arrive in hospital earlier).
ICH after treatment of acute stroke patients with rtPA might be avoided by not treating patients at high predicted risk for ICH. At least 7 multivariate models have been constructed to predict the risk of ICH after treatments with rtPA. [22] [23] [24] [25] [26] [27] [28] Each model had modest predictive power in validation datasets, although none of these studies reported the raw associations between factors and post-rtPA ICH. However, none of these studies establishes whether treatment with rtPA was of less benefit to those with a higher predicted risk of post-rtPA ICH. There are 2 potentially modifiable baseline clinical variables associated with post-rtPA hemorrhage, increased blood glucose, and increased blood pressure. Neither the lowering of blood glucose 29 nor the lowering of blood pressure 30 is associated with less death or disability after acute stroke in completed randomized trials, but it is possible that correction of increased blood pressure or glucose might mitigate the increased risk of ICH with rtPA treatment.
The findings of this review may help clinicians to make modest predictions about the risk of ICH in individual patients. ICH after rtPA is more likely to be seen in patients who are older, with substantial comorbidities and more severe strokes, and in those using antiplatelet agents and with visible abnormalities on baseline computed tomography imaging. This might aid communication with patients and their relatives, although this probably should not influence the decision whether to administer rtPA, because no variable measured at baseline-other than time to treatment-has shown a significant interaction with the net benefit of treatment on subsequent death or disability.
Conclusions
Factors that predict ICH after treatment with rtPA are similar to the factors that predict poor outcome after stroke. The modest association between these factors and post-rtPA ICH means accurate identification of those patients most likely to experience an ICH with treatment is difficult. Without clear evidence that ischemic stroke patients with higher predicted risk of post-rtPA ICH experience net harm or have no worthwhile benefit from treatment, these data do not provide a reliable means to select the patients least likely to be harmed and most likely to gain net benefit from intravenous rtPA. ECASS 1 hemorrhagic events were classified as HI types I and II and PH types I and II. HI I is defined as small petechiae along the margins of the infarct, while HI II represents more confluent petechiae within the infracted area, but without space-occupying effect. PH I is defined as blood clot not exceeding 30% ofthe infarcted area with some mild space-occupying effect, and PH II represents dense blood clot(s) exceeding 30% of the infarct volume with significant space-occupying effect. CT at 24 hrs and 6-8 days and discretion of investigator. (16) NINDS symptomatic: Symptomatic ICH was defined as a CT-documented hemorrhage that was temporally related to deterioration in the patient's clinical condition in the judgment of the clinical investigator. Symptomatic ICH attributable to study medication was defined, before completion of the randomized study, as symptomatic hemorrhage that occurred within 36 hours from treatment onset. Scans at 24h 7-10 days and discretion of investigator. (13) NINDS asymptomatic: Asymptomatic ICH was defined as CT-documented hemorrhage that was not associated with deterioration in the patient's neurological condition in the judgment of the clinical investigator. Scans at 24h 7-10 days and discretion of investigator. (13) ECASS 2: symptomatic: Symptomatic intracranial haemorrhage was defined as blood at any site in the brain on the CT scan (as assessed by the CT reading panel, independently of the assessment by the investigator), documentation by the investigator of clinical deterioration, or adverse events indicating clinical worsening (eg, drowsiness, increase of hemiparesis) or causing a decrease in the NIHSS score of 4 or more points. Scans at 22-36 hr and day 7. (14) ECASS 3: symptomatic intracranial hemorrhage was defined as any apparently extravascular blood in the brain or within the cranium that was associated with clinical deterioration, as defined by an increase of 4 points or more in the score on the NIHSS, or that led to death and that was identified as the predominant cause of the neurologic deterioration. Scans at 22-36 hr and at discretion of investigator. (15) SIST MOST: symptomatic intracerebral haemorrhage and death within 3 months. Symptomatic intracerebral haemorrhage, per the SITS-MOST protocol, was defined as local or remote parenchymal haemorrhage type 2 on the 22-36 h post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline, or from the lowest NIHSS value between baseline and 24 h, or leading to death. 
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